Evotec SE (NASDAQ:EVO – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

German stocks are a bit subdued Tuesday morning with investors making cautious moves amid a lack of significant triggers. Data on ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership ...

Despite macroeconomic uncertainty and geopolitical instability, the S&P 500 rallied to new all-time highs in 2024.

Halozyme backs FY24 adjusted EPS view $4.00-$4.20, consensus $4.14 Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...